AbCellera Biologics (ABCL) Q1 2025 earnings summary

Executive summary

• Transitioned to a clinical-stage biotech, advancing ABCL635 and ABCL575 toward Phase 1 trials in H2/Q3 2025, with ABCL635 targeting non-hormonal menopausal vasomotor symptoms and ABCL575 focused on extended dosing in dermatology/immunology indications.

• Over 20 internal and co-development programs in the pipeline, with 97 cumulative partner-initiated program starts and 16 molecules in the clinic.

• Major investments in clinical manufacturing and headquarters are nearing completion, with new facility expected online by end of 2025.

• Ended Q1 2025 with over $800 million in available liquidity, including $630–$633 million in cash, cash equivalents, and marketable securities, and $178–$180 million in government funding.

• Net loss for Q1 2025 widened to $45.6–$46 million, or $(0.15) per share, driven by increased R&D investment and lower revenue.

Financial highlights

• Q1 2025 revenue was $4–$4.2 million, down 57–58% year-over-year, mainly from research fees.

• R&D expenses increased to $42.5–$43 million, reflecting higher investment in internal programs.

• Sales and marketing expenses were $2.8–$3 million, and G&A expenses were $9.8–$16.2 million, both slightly lower year-over-year.

• Net loss margin increased to approximately (108%) due to lower revenue and higher R&D spend.

• Cash and marketable securities represented 45% of total assets at quarter-end.

Outlook and guidance

• Phase 1 clinical trials for ABCL635 and ABCL575 are expected to begin in Q3/H2 2025, with key safety and early efficacy readouts anticipated in 2026.

• Continued investment in platform, manufacturing, and internal pipeline, with liquidity expected to cover needs for at least 36 months.

• Additional development candidate nominations for CTA-enabling studies expected in H1 2025.